Preparing the structured Flagship evidence library.
Flagship peptide screening profile
A ranked discovery registry is available. No legacy governed direct-evidence relationship has yet been promoted for this profile; the zero below is intentional and must not be interpreted as evidence of absence.
global evidence atlas
This is a deduplicated PubMed screening registry—not a claim that every mention directly proves efficacy or safety. Machine proposals remain visibly separate from governed human appraisal.
Investigational boundary: Cagrilintide is not presented here as FDA-approved, and screening records must not be interpreted as established clinical benefit.
118 matching records · ranked 2026-09-18
Page 1 of 5
BMJ medicine · 2026 · PMID 42688617 · DOI 10.1136/bmjmed-2026-003026
Weight loss and obesity · Type 2 diabetes and glycemia · Safety and tolerability · Mechanism and pharmacology · Comparative effectiveness
The American journal of cardiology · 2026 May 15 · PMID 41759565 · DOI 10.1016/j.amjcard.2026.02.030
Weight loss and obesity · CagriSema combination evidence · Monotherapy evidence · Comparative effectiveness
Diabetes, obesity & metabolism · 2026 Jun · PMID 41834765 · DOI 10.1111/dom.70667
Weight loss and obesity · CagriSema combination evidence · Safety and tolerability · Comparative effectiveness
Endocrinology, diabetes & metabolism · 2026 May · PMID 42175595 · DOI 10.1002/edm2.70247
Weight loss and obesity · Amylin biology · Type 2 diabetes and glycemia · Comparative effectiveness
Annals of medicine and surgery (2012) · 2026 Aug · PMID 42583410 · DOI 10.1097/MS9.0000000000005353
Weight loss and obesity · Amylin biology · CagriSema combination evidence · Comparative effectiveness
Journal of diabetes and metabolic disorders · 2026 Jun · PMID 42180166 · DOI 10.1007/s40200-026-01942-3
Weight loss and obesity · CagriSema combination evidence · Safety and tolerability
Endocrinology, diabetes & metabolism · 2026 Jul · PMID 42207966 · DOI 10.1002/edm2.70248
Weight loss and obesity · CagriSema combination evidence · Comparative effectiveness
Annals of internal medicine · 2026 Aug · PMID 42296503 · DOI 10.7326/ANNALS-24-03764
Weight loss and obesity · Mechanism and pharmacology · Comparative effectiveness
BMJ (Clinical research ed.) · 2024 Jan 29 · PMID 38286487 · DOI 10.1136/bmj-2023-076410
Weight loss and obesity · Amylin biology · Type 2 diabetes and glycemia · Mechanism and pharmacology · Comparative effectiveness
Obesity (Silver Spring, Md.) · 2026 Sep · PMID 41189318 · DOI 10.1002/oby.70054
Weight loss and obesity · Safety and tolerability
BMJ (Clinical research ed.) · 2026 Jul 8 · PMID 42419792 · DOI 10.1136/bmj-2026-372161
Weight loss and obesity · Comparative effectiveness
Naunyn-Schmiedeberg's archives of pharmacology · 2026 Aug 17 · PMID 42608559 · DOI 10.1007/s00210-026-05809-5
Weight loss and obesity · CagriSema combination evidence
Indian journal of endocrinology and metabolism · 2024 Sep-Oct · PMID 39676787 · DOI 10.4103/ijem.ijem_45_24
Weight loss and obesity · CagriSema combination evidence · Monotherapy evidence · Safety and tolerability
Annals of internal medicine · 2026 Sep 1 · PMID 42673585 · DOI 10.7326/ANNALS-25-05519
Weight loss and obesity · Amylin biology · Type 2 diabetes and glycemia · Safety and tolerability · Mechanism and pharmacology
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2024 Feb · PMID 38242040 · DOI 10.1016/j.biopha.2024.116150
Weight loss and obesity · Safety and tolerability · Comparative effectiveness
The lancet. Diabetes & endocrinology · 2026 Jun · PMID 42009015 · DOI 10.1016/S2213-8587(25)00402-4
Weight loss and obesity · CagriSema combination evidence · Monotherapy evidence · Type 2 diabetes and glycemia · Safety and tolerability · Comparative effectiveness · Ongoing development
BMJ open · 2025 Sep 21 · PMID 40976663 · DOI 10.1136/bmjopen-2025-103668
Ongoing development
The lancet. Diabetes & endocrinology · 2026 Aug · PMID 42251859 · DOI 10.1016/S2213-8587(26)00125-7
CagriSema combination evidence · Type 2 diabetes and glycemia · Comparative effectiveness · Ongoing development
The lancet. Diabetes & endocrinology · 2026 Aug · PMID 42251860 · DOI 10.1016/S2213-8587(26)00126-9
CagriSema combination evidence · Type 2 diabetes and glycemia · Safety and tolerability · Ongoing development
Lancet (London, England) · 2026 Jul 4 · PMID 42251856 · DOI 10.1016/S0140-6736(26)01022-6
CagriSema combination evidence · Type 2 diabetes and glycemia · Ongoing development
Cureus · 2025 Mar · PMID 40206909 · DOI 10.7759/cureus.80321
Weight loss and obesity · CagriSema combination evidence
Hypertension (Dallas, Tex. : 1979) · 2026 Feb · PMID 41328546 · DOI 10.1161/HYPERTENSIONAHA.125.26055
Weight loss and obesity · CagriSema combination evidence
Clinical pharmacokinetics · 2026 Jul · PMID 42228334 · DOI 10.1007/s40262-026-01654-0
Safety and tolerability · Mechanism and pharmacology
The lancet. Gastroenterology & hepatology · 2026 Sep · PMID 42456707 · DOI 10.1016/S2468-1253(26)00123-8
CagriSema combination evidence · Safety and tolerability
Expert opinion on investigational drugs · 2025 Mar · PMID 40022548 · DOI 10.1080/13543784.2025.2472408
Weight loss and obesity · Amylin biology · Mechanism and pharmacology